BIOSKIN: A Protocol for the Copenhagen Translational Skin Immunology Biobank and Research Programme

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

BIOSKIN : A Protocol for the Copenhagen Translational Skin Immunology Biobank and Research Programme. / Løvendorf, Marianne Bengtson; Johansen, Jeanne Duus; Skov, Lone.

I: BMJ Open, Bind 14, Nr. 2, e077207, 2024.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Løvendorf, MB, Johansen, JD & Skov, L 2024, 'BIOSKIN: A Protocol for the Copenhagen Translational Skin Immunology Biobank and Research Programme', BMJ Open, bind 14, nr. 2, e077207. https://doi.org/10.1136/bmjopen-2023-077207

APA

Løvendorf, M. B., Johansen, J. D., & Skov, L. (2024). BIOSKIN: A Protocol for the Copenhagen Translational Skin Immunology Biobank and Research Programme. BMJ Open, 14(2), [e077207]. https://doi.org/10.1136/bmjopen-2023-077207

Vancouver

Løvendorf MB, Johansen JD, Skov L. BIOSKIN: A Protocol for the Copenhagen Translational Skin Immunology Biobank and Research Programme. BMJ Open. 2024;14(2). e077207. https://doi.org/10.1136/bmjopen-2023-077207

Author

Løvendorf, Marianne Bengtson ; Johansen, Jeanne Duus ; Skov, Lone. / BIOSKIN : A Protocol for the Copenhagen Translational Skin Immunology Biobank and Research Programme. I: BMJ Open. 2024 ; Bind 14, Nr. 2.

Bibtex

@article{0c29100978f5459880240fdc0bf2b650,
title = "BIOSKIN: A Protocol for the Copenhagen Translational Skin Immunology Biobank and Research Programme",
abstract = "Introduction Psoriasis, atopic dermatitis and contact dermatitis are common chronic inflammatory skin diseases that have a significant impact on individuals and society. Methods and analysis The Copenhagen Translational Skin Immunology Biobank and Research Programme (BIOSKIN) is a translational biobank and research study that aims to prospectively collect high-quality biological samples and clinical data from 3000 patients with psoriasis, atopic dermatitis and contact dermatitis over a minimum period of 5 years. The longitudinal open design allows participants to enter and leave the study at different time points depending on their disease and treatment course. At every visit, the investigator collects biological samples, conducts interviews and assembles self-reported questionnaires on disease-specific and general health-related information. Clinical examination and biological sampling will be conducted at enrolment, during and after disease flare, before and after initiation of new treatment and at least once per year. The clinical examination includes dermatological verification of diagnosis, evaluation of disease severity and detailed information on phenotype. The biological samples include blood and when accessible and relevant, skin biopsies, tape strips and skin swabs. The data collected will undergo rigorous statistical analysis using appropriate analytical methods. As of December 2023, 825 patients have been enrolled in the study. Ethics and dissemination The study is approved by the Scientific Ethical Committee of the Capital Region (H-21032986) and the Danish Data Protection Agency. Results will be published in peer-reviewed scientific journals and presented at national and international conferences. ",
author = "L{\o}vendorf, {Marianne Bengtson} and Johansen, {Jeanne Duus} and Lone Skov",
note = "Publisher Copyright: {\textcopyright} 2024 Author(s) (or their employer(s)).",
year = "2024",
doi = "10.1136/bmjopen-2023-077207",
language = "English",
volume = "14",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "2",

}

RIS

TY - JOUR

T1 - BIOSKIN

T2 - A Protocol for the Copenhagen Translational Skin Immunology Biobank and Research Programme

AU - Løvendorf, Marianne Bengtson

AU - Johansen, Jeanne Duus

AU - Skov, Lone

N1 - Publisher Copyright: © 2024 Author(s) (or their employer(s)).

PY - 2024

Y1 - 2024

N2 - Introduction Psoriasis, atopic dermatitis and contact dermatitis are common chronic inflammatory skin diseases that have a significant impact on individuals and society. Methods and analysis The Copenhagen Translational Skin Immunology Biobank and Research Programme (BIOSKIN) is a translational biobank and research study that aims to prospectively collect high-quality biological samples and clinical data from 3000 patients with psoriasis, atopic dermatitis and contact dermatitis over a minimum period of 5 years. The longitudinal open design allows participants to enter and leave the study at different time points depending on their disease and treatment course. At every visit, the investigator collects biological samples, conducts interviews and assembles self-reported questionnaires on disease-specific and general health-related information. Clinical examination and biological sampling will be conducted at enrolment, during and after disease flare, before and after initiation of new treatment and at least once per year. The clinical examination includes dermatological verification of diagnosis, evaluation of disease severity and detailed information on phenotype. The biological samples include blood and when accessible and relevant, skin biopsies, tape strips and skin swabs. The data collected will undergo rigorous statistical analysis using appropriate analytical methods. As of December 2023, 825 patients have been enrolled in the study. Ethics and dissemination The study is approved by the Scientific Ethical Committee of the Capital Region (H-21032986) and the Danish Data Protection Agency. Results will be published in peer-reviewed scientific journals and presented at national and international conferences.

AB - Introduction Psoriasis, atopic dermatitis and contact dermatitis are common chronic inflammatory skin diseases that have a significant impact on individuals and society. Methods and analysis The Copenhagen Translational Skin Immunology Biobank and Research Programme (BIOSKIN) is a translational biobank and research study that aims to prospectively collect high-quality biological samples and clinical data from 3000 patients with psoriasis, atopic dermatitis and contact dermatitis over a minimum period of 5 years. The longitudinal open design allows participants to enter and leave the study at different time points depending on their disease and treatment course. At every visit, the investigator collects biological samples, conducts interviews and assembles self-reported questionnaires on disease-specific and general health-related information. Clinical examination and biological sampling will be conducted at enrolment, during and after disease flare, before and after initiation of new treatment and at least once per year. The clinical examination includes dermatological verification of diagnosis, evaluation of disease severity and detailed information on phenotype. The biological samples include blood and when accessible and relevant, skin biopsies, tape strips and skin swabs. The data collected will undergo rigorous statistical analysis using appropriate analytical methods. As of December 2023, 825 patients have been enrolled in the study. Ethics and dissemination The study is approved by the Scientific Ethical Committee of the Capital Region (H-21032986) and the Danish Data Protection Agency. Results will be published in peer-reviewed scientific journals and presented at national and international conferences.

U2 - 10.1136/bmjopen-2023-077207

DO - 10.1136/bmjopen-2023-077207

M3 - Journal article

C2 - 38401898

AN - SCOPUS:85185900459

VL - 14

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 2

M1 - e077207

ER -

ID: 384866369